Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cytokinetics (CYTK) Assets Average (2016 - 2025)

Cytokinetics (CYTK) has disclosed Assets Average for 14 consecutive years, with $1.4 billion as the latest value for Q4 2025.

  • On a quarterly basis, Assets Average changed N/A to $1.4 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.4 billion, a N/A change, with the full-year FY2023 number at $919.5 million, down 0.92% from a year prior.
  • Assets Average was $1.4 billion for Q4 2025 at Cytokinetics, up from $1.3 billion in the prior quarter.
  • In the past five years, Assets Average ranged from a high of $1.5 billion in Q3 2024 to a low of $555.4 million in Q1 2021.
  • A 5-year average of $970.4 million and a median of $848.8 million in 2022 define the central range for Assets Average.
  • Peak YoY movement for Assets Average: skyrocketed 103.31% in 2021, then dropped 25.15% in 2023.
  • Cytokinetics' Assets Average stood at $834.4 million in 2021, then increased by 25.28% to $1.0 billion in 2022, then decreased by 25.15% to $782.5 million in 2023, then surged by 89.14% to $1.5 billion in 2024, then fell by 3.34% to $1.4 billion in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Assets Average are $1.4 billion (Q4 2025), $1.3 billion (Q3 2025), and $1.2 billion (Q2 2025).